Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)

NCT00885833 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

5

Enrollment

NETWORK

Sponsor class

Conditions

Wiskott-Aldrich Syndrome

Interventions

DRUG: Fludarabine, Busulfan, Thymoglobulin

Sponsor

The Korean Society of Pediatric Hematology Oncology